Contract research organizations make good money providing critical services to young biotech and drug development companies early on. But often, those companies are cash-strapped at the stage when they need a CRO. That’s why some CROs are becoming stakeholders in the companies they work with, offering cash or services for equity in life science startups…
CROs as Early-Stage Life Science Investors? ‘It’s the Model of the Future,’ One Says
Comments are closed.